Purchase this article with an account.
A.M. Bovell, K.F. Damji, W.G. Hodge, W. Rock, R. Buhrmann; A Randomized Clinical Trial of Selective Laser Trabeculoplasty (SLT) vs. Argon Laser Trabeculoplasty (ALT) - Intraocular pressure Lowering Results after 3 Years . Invest. Ophthalmol. Vis. Sci. 2003;44(13):101.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: SLT is a q-switched, melanosome specific laser used to lower intraocular pressure (IOP) in open angle glaucoma. Benefits of SLT over conventional ALT include preservation of the trabecular meshwork architecture, markedly lower energy requirement, ease of use, and potential for repeatability. We conducted a randomized clinical trial, comparing efficacy of SLT to ALT, and now report 3 year data. Methods: 165 eyes with open angle glaucoma on maximal tolerated medical therapy were enrolled at the time of this analysis and randomized to undergo either SLT or ALT, using standard treatment parameters. 91 eyes have reached 3 years and at the time of analysis, data was available for 69 eyes. Primary outcome was change in IOP from pretreatment baseline. Univariate and multivariate analyses were performed. Results: Baseline comparison was similar between SLT (n= 36) and ALT (n=33) groups including IOP (23.8mmHg +/- 4.2 and 23.5 mmHg +/- 3.8, respectively). 3 year IOP drops were similar in the SLT (-6.5 +/- 6.76, n=36) and ALT (-6.0 +/- 4.67, n=33) groups. There was no statistically significant difference in IOP change between groups. There were an equivalent number of medication changes in each group. Conclusions: SLT appears to be equivalent to ALT in IOP lowering at 3 years.
This PDF is available to Subscribers Only